Introduction to Inhalation and Nasal Drug Product Quality
Nasal and inhalation therapies have gained significant traction in the pharmaceutical sector. Maintaining high quality for any medicinal product is essential. Regulatory organizations, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established guidelines for assessing and ensuring the quality of inhalation and nasal drug products. Consequently, a thorough understanding of the quality standards for these therapies is crucial. This paper provides pharmaceutical companies with valuable insights into the key elements that influence product quality, thereby enhancing the safety and effectiveness of these therapies.
Quality Considerations for Inhalation and Nasal Medicinal Products
The FDA and EMA guidelines emphasize stringent quality control measures for orally inhaled and nasal drug products.
Various quality aspects are crucial in managing the challenges associated with this specific range of drug products, including:
- Drug product composition, encompassing the attributes of both drug substance and excipients
- Critical quality attributes and critical process parameters of the finished drug product
- Selection and performance of the container closure system
- Product behavior during stability studies and
- Labeling information
This paper provides comprehensive information on the drug development studies required to facilitate the design of experiments that meet the standards of US and EU regulators. Summarizing these quality recommendations in one place will help drug developers reduce the “back-to-bench” incidents and increase efficiency in the application review process, thereby ensuring the timely availability of treatments to end-users.